Profusa, Inc. (PFSA) stock
PFSANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as NVACW
$0.45−0.01 (-2.61%)
Close on Nov 13, 2026Market cap $1.13MP/E –Yield –
Profusa r&d expenses
Research and development expenses are spending on new products and technology.
Profusa's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.45M, up 90.6% year over year. For fiscal 2025 it was $2.80M, up 74.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | +74.4% |
| FY2024 | Dec 31, 2024 | $1.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $222.00K | -69.3% |
| Q2 FY2026 | Jun 30, 2026 | $823.00K | +109.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.15M | +164.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.26M | +384.6% |
| Q3 FY2025 | Sep 30, 2025 | $722.00K | +75.7% |
| Q2 FY2025 | Jun 30, 2025 | $393.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $434.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $259.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $411.00K | – |
See a number that looks wrong?